Keyword: Beam Therapeutics
Nearly seven months after raising $135 million in its series B round, Beam Therapeutics filed Friday to raise up to $100 million in its Nasdaq IPO.
Broad Institute researchers have developed an RNA-editing strategy that they believe could someday treat brain diseases like Alzheimer’s.
Verve Therapeutics is launching with $58.5 million access to CRISPR and base-editing tech and cardiologist and geneticist Sekar Kathiresan as CEO.
Beam raises a healthy $135 million in second-round funding that will be used to advance its single-base approach to gene editing.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
Editing genomes, one letter at a time.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.
Feng Zhang's latest CRISPR company, Beam Therapeutics, officially came out of stealth Monday with $87 million in series A funding.
